JP2016510309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510309A5 JP2016510309A5 JP2015547567A JP2015547567A JP2016510309A5 JP 2016510309 A5 JP2016510309 A5 JP 2016510309A5 JP 2015547567 A JP2015547567 A JP 2015547567A JP 2015547567 A JP2015547567 A JP 2015547567A JP 2016510309 A5 JP2016510309 A5 JP 2016510309A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- mer
- axl
- tyro3
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims 56
- 101150098329 Tyro3 gene Proteins 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 20
- 239000000562 conjugate Substances 0.000 claims 16
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 10
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 10
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000000863 peptide conjugate Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102220529619 ATP synthase subunit a_H61Y_mutation Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102220567663 Matrilysin_V92A_mutation Human genes 0.000 claims 1
- 102220567664 Matrilysin_V92D_mutation Human genes 0.000 claims 1
- 102220567707 Matrilysin_V92G_mutation Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102220344853 c.257A>G Human genes 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102200005981 rs104894561 Human genes 0.000 claims 1
- 102200045113 rs104894683 Human genes 0.000 claims 1
- 102200032988 rs104894959 Human genes 0.000 claims 1
- 102220219923 rs1060503389 Human genes 0.000 claims 1
- 102220218297 rs1060503453 Human genes 0.000 claims 1
- 102220012991 rs111033344 Human genes 0.000 claims 1
- 102220003706 rs137852315 Human genes 0.000 claims 1
- 102200063970 rs150190385 Human genes 0.000 claims 1
- 102220265708 rs1555054052 Human genes 0.000 claims 1
- 102220245301 rs1555596673 Human genes 0.000 claims 1
- 102220005514 rs3180281 Human genes 0.000 claims 1
- 102220005273 rs33915112 Human genes 0.000 claims 1
- 102220005263 rs33948578 Human genes 0.000 claims 1
- 102200082936 rs33950507 Human genes 0.000 claims 1
- 102220005408 rs33984024 Human genes 0.000 claims 1
- 102220012959 rs377052919 Human genes 0.000 claims 1
- 102220135902 rs61731470 Human genes 0.000 claims 1
- 102220072209 rs727505205 Human genes 0.000 claims 1
- 102220098139 rs878852992 Human genes 0.000 claims 1
- 102220099378 rs878854009 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737276P | 2012-12-14 | 2012-12-14 | |
| US61/737,276 | 2012-12-14 | ||
| PCT/US2013/074786 WO2014093690A1 (en) | 2012-12-14 | 2013-12-12 | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098435A Division JP6832887B2 (ja) | 2012-12-14 | 2018-05-23 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510309A JP2016510309A (ja) | 2016-04-07 |
| JP2016510309A5 true JP2016510309A5 (OSRAM) | 2017-02-02 |
| JP6345690B2 JP6345690B2 (ja) | 2018-06-20 |
Family
ID=50934967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547567A Active JP6345690B2 (ja) | 2012-12-14 | 2013-12-12 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
| JP2018098435A Expired - Fee Related JP6832887B2 (ja) | 2012-12-14 | 2018-05-23 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098435A Expired - Fee Related JP6832887B2 (ja) | 2012-12-14 | 2018-05-23 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9822347B2 (OSRAM) |
| EP (2) | EP2931265B3 (OSRAM) |
| JP (2) | JP6345690B2 (OSRAM) |
| AU (3) | AU2013359179B2 (OSRAM) |
| CA (1) | CA2894539C (OSRAM) |
| DK (2) | DK2931265T6 (OSRAM) |
| ES (2) | ES2862335T3 (OSRAM) |
| FI (1) | FI2931265T6 (OSRAM) |
| NO (1) | NO3049208T3 (OSRAM) |
| PT (2) | PT2931265T (OSRAM) |
| WO (1) | WO2014093690A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011207381B2 (en) * | 2010-01-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| ES2862335T3 (es) | 2012-12-14 | 2021-10-07 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| CA2971406A1 (en) * | 2014-12-18 | 2016-06-23 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
| US20200289613A1 (en) * | 2017-11-04 | 2020-09-17 | Aravive Biologics, Inc. | Methods of treating metastatic cancers using axl decoy receptors |
| WO2023039254A1 (en) * | 2021-09-11 | 2023-03-16 | Aravive Inc | Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5538861A (en) * | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US20030166110A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| WO2004108748A2 (en) | 2002-09-24 | 2004-12-16 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| JP2006524496A (ja) | 2003-04-18 | 2006-11-02 | ノバルティス アクチエンゲゼルシャフト | 骨関節炎の診断および処置のためのチロシンキナーゼを標的化する方法および組成物 |
| JP2005278631A (ja) | 2004-03-04 | 2005-10-13 | National Institute Of Advanced Industrial & Technology | Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法 |
| EP1825005B1 (en) | 2004-11-24 | 2015-07-15 | The Regents of the University of Colorado, a body corporate | Mer diagnostic and therapeutic agents |
| WO2006118308A1 (ja) | 2005-05-02 | 2006-11-09 | Toray Industries, Inc. | 食道ガン及び食道ガン転移診断のための組成物及び方法 |
| US8168415B2 (en) * | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
| WO2008128072A2 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
| EP2170395A1 (en) | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| KR20120035145A (ko) * | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| AU2011207381B2 (en) * | 2010-01-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| US10844106B2 (en) | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| ES2862335T3 (es) * | 2012-12-14 | 2021-10-07 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| WO2015030849A1 (en) * | 2013-08-30 | 2015-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | High-affinity binding to gas6 |
| CA2909669C (en) * | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| CA2971406A1 (en) * | 2014-12-18 | 2016-06-23 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
-
2013
- 2013-12-12 ES ES17196662T patent/ES2862335T3/es active Active
- 2013-12-12 US US14/650,854 patent/US9822347B2/en not_active Expired - Fee Related
- 2013-12-12 EP EP13862780.7A patent/EP2931265B3/en active Active
- 2013-12-12 DK DK13862780.7T patent/DK2931265T6/da active
- 2013-12-12 EP EP17196662.5A patent/EP3326622B1/en active Active
- 2013-12-12 FI FIEP13862780.7T patent/FI2931265T6/fi active
- 2013-12-12 WO PCT/US2013/074786 patent/WO2014093690A1/en not_active Ceased
- 2013-12-12 CA CA2894539A patent/CA2894539C/en active Active
- 2013-12-12 ES ES13862780T patent/ES2665323T7/es active Active
- 2013-12-12 AU AU2013359179A patent/AU2013359179B2/en not_active Ceased
- 2013-12-12 JP JP2015547567A patent/JP6345690B2/ja active Active
- 2013-12-12 PT PT138627807T patent/PT2931265T/pt unknown
- 2013-12-12 PT PT171966625T patent/PT3326622T/pt unknown
- 2013-12-12 DK DK17196662.5T patent/DK3326622T3/da active
-
2014
- 2014-06-30 NO NO14741534A patent/NO3049208T3/no unknown
-
2017
- 2017-10-13 US US15/783,850 patent/US11136563B2/en not_active Expired - Fee Related
- 2017-12-06 AU AU2017272193A patent/AU2017272193A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098435A patent/JP6832887B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-02 AU AU2019210662A patent/AU2019210662B2/en not_active Ceased
-
2021
- 2021-09-02 US US17/465,203 patent/US20220220458A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510309A5 (OSRAM) | ||
| JP2016000731A5 (OSRAM) | ||
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
| WO2018098363A3 (en) | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x | |
| RU2018132044A (ru) | Антитела против тау | |
| WO2021041715A3 (en) | Compositions including igg fc mutations and uses thereof | |
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| NL300919I2 (nl) | Brodalumab | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2014043446A5 (OSRAM) | ||
| JP2019514361A5 (OSRAM) | ||
| WO2014074532A3 (en) | Compositions and methods for modulating cell signaling | |
| CA2953714C (en) | Anti-tnfa antibodies with ph-dependent antigen binding | |
| JP2015212284A5 (OSRAM) | ||
| MX384984B (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| HK1198832A1 (en) | Fn14 binding proteins and uses thereof | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
| EA030777B9 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| EP3339322A3 (en) | Immunoglobulin single variable domain antibodies with a c-terminal extension for reduced immunogenicity | |
| WO2012088247A3 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| JP2017529870A5 (OSRAM) | ||
| WO2007146401A3 (en) | Denatured collagen peptides and uses thereof |